On October 20, 2023, Camac Partners LLC announced that it has filed an amended class action and derivative complaint against the directors of the Forte Biosciences Inc and naming the Company as a nominal defendant, the class claim alleges the directors breached their fiduciary duties by causing the Company to enter into the Private Placement, setting the Annual Meeting record date for a date after the Private Placement closed, and holding the Annual Meeting more than 13 months after the 2022 annual meeting, and the amended complaint purports to bring a 2nd claim for wrongful dilution derivatively on behalf of the Company. In addition, Camac Fund stated that the derivative claim alleges the directors wrongfully diluted Camac Fund and other stockholders by causing the Company to enter the Private Placement in bad faith and for the purpose of entrenchment and not permitting Camac Fund and other stockholders to participate.